SEC Filing Summary: Galectin Therapeutics Inc. (GALT)
Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on April 14, 2022. The report serves to disseminate a press release (Exhibit 99.1) issued on the same date. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market under the symbol GALT.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain audited financial statements or quarterly results.
Material Changes
No material financial changes versus a prior comparable period are detailed in this document. The filing solely references the issuance of a press release.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described within the body of this Form 8-K. These details are contained within the attached press release (Exhibit 99.1), the text of which is not included in the provided input.
Key Facts for Investor Verification
- Verify the content of the press release filed as Exhibit 99.1 to understand the specific event triggering this filing.
- Confirm the company's current cash position and runway by reviewing the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Note that the filing was signed by Jack W. Callicutt, Chief Financial Officer, on April 14, 2022.